Improving treatment for liposarcoma by understanding drug resistance
Official title: Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance
Funded at Sloan-Kettering Inst Can Research · NIH-11228162 · Data updated 2026-11-12
This study is looking to help patients with dedifferentiated liposarcoma by finding better ways to use a cancer treatment called CDK4/6 inhibitors, especially for those who don’t respond well to it, by testing a combination of two drugs, palbociclib and mirdametinib, to see if it can improve their treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 3, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $727,732 |
| NIH project number | 1R01CA296835-01A1 |
| Project ID | NIH-11228162 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with dedifferentiated liposarcoma who are undergoing treatment with CDK4/6 inhibitors.
✕Less likely to help
Patients with other types of cancer or those who do not have dedifferentiated liposarcoma may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of CDK4/6 inhibitors, a type of cancer therapy, specifically for patients with dedifferentiated liposarcoma. The study aims to understand why some patients develop resistance to these drugs and how to overcome it through combination therapies. By analyzing the biological processes involved in cellular senescence and resistance, researchers will conduct a clinical trial to evaluate the efficacy of combining palbociclib with another drug, mirdametinib. This approach seeks to improve treatment outcomes for patients who may not respond well to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with liposarcoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using CDK4/6 inhibitors for liposarcoma, indicating that this approach may build on existing knowledge and success.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Tap, William D. — Sloan-Kettering Inst Can Research
- Study coordinator: Tap, William D.
Related research
Other NIH-funded projects on the same topics.
-
Dissecting how liposarcoma cells differentiate and interact with immune cells to find new therapies
This grant explores how liposarcoma cancer cells differentiate and how immune cells in the tumor environment influence progression, with the aim of finding new treatment options for patients.
-
Preclinical mouse models of liposarcoma for immuno-oncology applications
A research grant is studying immune-related ways to understand and treat liposarcoma using a specially engineered mouse model that mimics human tumors.
-
Improving CDK4/6 therapy for liposarcoma by understanding resistance
This project tests a combination therapy to overcome resistance to CDK4/6 inhibitors in patients with dedifferentiated liposarcoma and aims to improve treatment results.
-
Finding biomarkers to predict treatment benefits for a specific type of cancer
This study is looking at a new treatment approach for people with a rare type of cancer called liposarcoma, by combining two medications to see if they can work better together, and it aims to find out which patients might benefit the most from this combination.
-
Investigating the immune environment of liposarcoma using genetically modified mice
This study is looking at how certain immune cells, called memory T cells, work in the environment of liposarcoma tumors to find new ways to improve treatment for patients with this type of cancer.
-
Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma
This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.